334 related articles for article (PubMed ID: 10169229)
41. Pharmaceuticals, patents, and politics: Canada and Bill C-22.
Lexchin J
Int J Health Serv; 1993; 23(1):147-60. PubMed ID: 8425783
[TBL] [Abstract][Full Text] [Related]
42. The importance of being first: evidence from Canadian generic pharmaceuticals.
Hollis A
Health Econ; 2002 Dec; 11(8):723-34. PubMed ID: 12457372
[TBL] [Abstract][Full Text] [Related]
43. Bill C-30: who wins and who loses in Canada's pharmaceutical patent battles?
Hollis A
Expert Opin Ther Pat; 2018 Jan; 28(1):1-3. PubMed ID: 28974123
[No Abstract] [Full Text] [Related]
44. After years of steady growth, winds of restraint blowing on prescription-drug industry.
Robinson A
CMAJ; 1995 Jul; 153(1):85-8. PubMed ID: 7796380
[TBL] [Abstract][Full Text] [Related]
45. TRIPS: generic irony.
Howarth GR
Br J Gen Pract; 2002 Jan; 52(474):57. PubMed ID: 11791819
[No Abstract] [Full Text] [Related]
46. US policy may encourage counterfeit drugs.
Bouchie A
Nat Biotechnol; 2003 Feb; 21(2):121. PubMed ID: 12560826
[No Abstract] [Full Text] [Related]
47. India's new patent laws may still hurt generic drug supplies.
Chatterjee P
Lancet; 2005 Apr 16-22; 365(9468):1378. PubMed ID: 15841559
[No Abstract] [Full Text] [Related]
48. Action alert: drug-patent bill could cost patients $3 billion+; hearing July 1.
AIDS Treat News; 1999 Jun; (No 321):8. PubMed ID: 11366716
[TBL] [Abstract][Full Text] [Related]
49. How drug life-cycle management patent strategies may impact formulary management.
Berger J; Dunn JD; Johnson MM; Karst KR; Shear WC
Am J Manag Care; 2016 Oct; 22(16 Suppl):S487-S495. PubMed ID: 28719222
[TBL] [Abstract][Full Text] [Related]
50. Drugmakers fight for good name. Stakes high, challenges many for providers who seek generic products.
Becker C
Mod Healthc; 2001 Aug; 31(35):28-33, 1. PubMed ID: 11550428
[TBL] [Abstract][Full Text] [Related]
51. Supreme Court rules against drug patent "evergreening".
Kondro W
CMAJ; 2006 Dec; 175(12):1508-9. PubMed ID: 17146081
[No Abstract] [Full Text] [Related]
52. Pharmaceutical policy in Italy: towards a structural change?
Ghislandi S; Krulichova I; Garattini L
Health Policy; 2005 Apr; 72(1):53-63. PubMed ID: 15760698
[TBL] [Abstract][Full Text] [Related]
53. European Commission targets drug firms over illegal patent protection.
Watson R
BMJ; 2010 Jan; 340():c268. PubMed ID: 20080819
[No Abstract] [Full Text] [Related]
54. Countering delays in introduction of generic drugs.
Lancet; 2002 Jan; 359(9302):181. PubMed ID: 11812545
[No Abstract] [Full Text] [Related]
55. High Court strikes down Merck's patent on alendronate.
Dyer O
BMJ; 2003 Feb; 326(7383):243. PubMed ID: 12560269
[No Abstract] [Full Text] [Related]
56. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
Dinh TQ
Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
[No Abstract] [Full Text] [Related]
57. . . . and Brazilian AIDS programme threatened by US trade action.
Int J Epidemiol; 2001 Apr; 30(2):413. PubMed ID: 11369751
[No Abstract] [Full Text] [Related]
58. [What drug companies actually do].
Tonby K
Tidsskr Nor Laegeforen; 2007 Jun; 127(13):1806. PubMed ID: 17599137
[No Abstract] [Full Text] [Related]
59. Overview of the Hatch-Waxman Act and its impact on the drug development process.
Mossinghoff GJ
Food Drug Law J; 1999; 54(2):187-94. PubMed ID: 11758572
[No Abstract] [Full Text] [Related]
60. The production of generic drugs in India.
Love J
BMJ; 2011 Mar; 342():d1694. PubMed ID: 21427048
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
